This study includes a registry-based, nationwide analysis to describe the clinical outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who underwent an allogeneic hematopoietic stem cell transplantation (HSCT) after a Tyrosine Kinase Inhibitors (TKI)-based treatment.
This was a retrospective nationwide analysis based on registry data collected by GITMO. Inclusion criteria were: 1) diagnosis of Ph+ ALL; age ≥18 years at transplant; 2) patients receiving first allogeneic HSCT from any donor (HLA-identical sibling donor (MSD), unrelated donor (UD) or alternative donor (haploidentical or cord blood) between 2005 and 2016 in a GITMO center; 3) TKI-based treatment prior to HSCT; 4) patients with available pre-transplant MRD status, as well as complete clinical data and outcome. Data were extracted from the GITMO Registry (PROMISE Registry). The endpoints of the study were: OS, progression-free survival (PFS), cumulative incidence of relapse (CIR), non-relapse mortality (NRM), cumulative incidence of extensive chronic graft versus host disease (cGVHD), rate of minimal residual disease (MRD) negativity and the rate of complete cytologic remission (CR) before and after transplant.
Study Type
OBSERVATIONAL
Enrollment
441
Hematopoietic Stem Cell Transplantation in Acute Leukemia Ph positive
GITMO Centers and GITMO CLINICAL OFFICE-AOU-IRCSS San Martino-Ge
Genova, Italy
University Hospital, Udine
Udine, Italy
Overall Survival (OS).
as reported
Time frame: 5 years
Rate of complete cytologic remission (CR) before and after transplant.
As reported
Time frame: Baseline and 3 months after SCT
Rate of minimal residual disease (MRD).
As reported
Time frame: Baseline and 3 months post SCT
Cumulative incidence of extensive chronic graft versus host disease (cGVHD).
as reported
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.